Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on HeraMED.
RELATED STOCKHEAD STORIES
Health & Biotech
Why HeraMED’s HeraBEAT device could replace CTG machines in emerging economies
Health & Biotech
Mayo Clinic approves clinical study of HeraMED’s HeraBEAT device
Health & Biotech
HeraMED taps into US employee benefit industry with Teleperinatal pilot
News
10 at 10: These ASX stocks have found their voice this morning
Health & Biotech
HeraMED taps into US healthcare market with eCare21 partnership
Stockhead TV
Health tech plays are seeing tectonic shifts in customer growth
Health & Biotech
Successful clinical study for HeraBEAT device showcases its telehealth application
Health & Biotech
HeraMED breaks into US healthcare market with eCare21 partnership
Health & Biotech
Here’s what the telehealth industry wants from ScoMo to maintain momentum
Health & Biotech
HeraMED opens up new medtech markets with clinical study milestone
Health & Biotech
Here are the top adopters of telehealth — and the biggest ASX winners
Health & Biotech
How tech is changing healthcare, and where professional ASX investors are looking
Health & Biotech
HeraMED announces new research collaboration with Mayo Clinic
Health & Biotech
US FDA approval is on the agenda for these 5 ASX small caps
News
Rise and Shine: What you need to know before the ASX opens
News
Rise and Shine: What you need to know before the ASX opens
Health & Biotech
